Overview

Observational Study of NovoNorm® in Subjects With Diabetes

Status:
Completed
Trial end date:
2005-03-25
Target enrollment:
Participant gender:
Summary
This study is conducted in Asia. The aim of this study is to review the safety and efficacy of Novonorm® (repaglinide) in post-marketing use.
Details
Lead Sponsor:
Novo Nordisk A/S
Treatments:
Repaglinide